celluar immunotherapies
GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million
February 20, 2020Business Services Cancer, cancer cells, celluar immunotherapies, immunotherapies
GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics. The deal sees GSK pay $50 million …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
